Aviva PLC Lowers Position in Moderna, Inc. (NASDAQ:MRNA)

Aviva PLC lowered its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 20.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 198,173 shares of the company's stock after selling 51,303 shares during the quarter. Aviva PLC owned about 0.05% of Moderna worth $8,240,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MRNA. Geode Capital Management LLC increased its stake in shares of Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after purchasing an additional 171,774 shares in the last quarter. Norges Bank bought a new stake in Moderna during the 4th quarter valued at $163,833,000. Charles Schwab Investment Management Inc. lifted its position in shares of Moderna by 9.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock worth $97,472,000 after acquiring an additional 211,426 shares in the last quarter. Pictet Asset Management Holding SA boosted its holdings in shares of Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock worth $73,447,000 after acquiring an additional 1,113,455 shares during the period. Finally, Amundi grew its position in shares of Moderna by 79.8% in the fourth quarter. Amundi now owns 1,206,273 shares of the company's stock valued at $52,075,000 after purchasing an additional 535,273 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on MRNA shares. UBS Group cut their target price on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th. Leerink Partners cut their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. JPMorgan Chase & Co. lowered their price objective on Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday, March 21st. Finally, Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Moderna has an average rating of "Hold" and an average target price of $58.70.

Remove Ads

Moderna Stock Up 6.9 %

Shares of NASDAQ:MRNA traded up $1.70 during midday trading on Friday, hitting $26.20. 10,999,018 shares of the stock traded hands, compared to its average volume of 7,181,061. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The stock has a market capitalization of $10.13 billion, a PE ratio of -2.82 and a beta of 2.23. The business's 50 day moving average is $31.56 and its two-hundred day moving average is $41.01.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.